Sign in Subscribe

Michelle Whirl-Carrillo, Director and Co-PI

November SNPits Summary

The November issue of UF Health Personalized Medicine Program's e-newsletter, SNPits, is out. This issue contains a summary of a recent paper by Nicholson and Formea in Clinical Chemistry that discusses implementing CPIC guidelines for CYP2D6 and codeine. The authors highlight some of the difficulties that may arise

Clinical evidence support for biomarkers on FDA-approved drug labels

A recent article by Wang et al. in JAMA Internal Medicine reviews the clinical evidence support found on FDA-approved drug labels that are listed on the FDA's Table of Pharmacogenomic Biomarkers in Drug Labeling. The authors found that many labels on the list did not contain, or reference,

ClinGen's GenomeConnect Patient Portal Launches

The NIH-funded Clinical Genome Resource (ClinGen) project has launched its patient portal at GenomeConnect. This site provides a patient registry for those who have already had or are contemplating genetic testing, or have family members who have been tested. It is open to the public for enrollment. Once a personal

SNP-its Study Summaries

The University of Florida Health Personalized Medicine Program has released "SNP-its" study summaries for pharmacogenomic articles with clinical relevance. The editorial team reviews articles from multiple journals and writes summaries for the ones most relevant to practicing clinicians. Those interested are welcome to subscribe to a monthly newsletter.

New CPIC Guideline: CYP2C9, HLA-B and Phenytoin

Guidelines regarding the use of pharmacogenomic tests for CYP2C9 and HLA-B in dosing phenytoin have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium (CPIC). Phenytoin is broadly used to treat epilepsy, but it has a narrow therapeutic index and wide inter-patient variability. Much of this

(Untitled)

PharmGKB is looking to fill a Scientific Curator position on our team. Below is a description of the responsibilities of a curator at PharmGKB. To apply, search for Scientific Curator - 61462 under Staff Positions at jobs.stanford.edu · Read pharmacogenomic experimental literature, analyzing articles for details about gene variant-drug

FDA-Approved Drug Labels, Pharmacogenomics and PharmGKB Evaluation

FDA-approved drug label standardization and pharmacogenomics People often use the wording "FDA drug labels" instead of "FDA-approved drug labels." To be clear, the FDA does not write drug labels; it is the responsibility of the drug company to provide them. The FDA reviews and approves labels,

CYP2D6 genotype and tamoxifen response: meta-analysis of heterogeneous population

Tamoxifen treatment results in substantial inter-individual variability of outcome, possibly due to genetic variability in CYP2D6. The clinical usefulness of CYP2D6 genotyping for prediction of tamoxifen outcome has not been established because of conflicting reports. This controversy is well illustrated by secondary analyses from 3 large adjuvant tamoxifen trials (ATAC,

CPIC publishes guidelines for HLA-B*15:02 Genotype and Carbamazepine Use

The Clinical Pharmacogenomics Implementation Consortium (CPIC) has published guidelines for the use of genetic test results for HLA-B*15:02 and carbamazepine in Clinical Pharmacology and Therapeutics. In cases where a patient is known to carry at least one HLA-B*15:02 allele, the guideline recommends that the clinician use

PharmGKB welcomes Julia Barbarino to the team

We are pleased to welcome scientific curator Julia Barbarino to the PharmGKB team. Julia recently completed her master's in Medical Molecular Genetics from the University of Aberdeen, Scotland, where her research focused on epigenetic modifications of the apolipoprotein E gene and their role in human longevity. While undertaking